Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting.
Valeria DaccòChiara RosazzaAlessandra MarianiCarmela RizzaNicolò IngianniErica NazzariVito TerlizziFrancesco Arturo BlasiGianfranco AlicandroPublished in: Pediatric pulmonology (2024)
Our data indicate that ETI therapy is well tolerated by children with CF and is effective in improving signs of lung function abnormalities from early childhood.